RAAS inhibitors do not increase the risk of COVID-19

According to five new studies, therapy with angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs) is not associated with an increased risk of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or with an increased risk of severe disease or in...

Descripción completa

Detalles Bibliográficos
Autor principal: Fernández-Ruiz, Irene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Research Highlight
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7243952/
https://www.ncbi.nlm.nih.gov/pubmed/32444693
http://dx.doi.org/10.1038/s41569-020-0401-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7243952/
https://www.ncbi.nlm.nih.gov/pubmed/32444693
http://dx.doi.org/10.1038/s41569-020-0401-0

Ejemplares similares